Epidermal growth factor receptor (EGFR)-targeting antibodies cetuximab and panitumumab are available treatment options for approximately 40% of patients with metastatic colorectal cancer (mCRC).1 Patient selection based on RAS and BRAF wild-type status and sidedness has improved overall response rates and survival outcomes. This evidence concerns the gene EGFR and metastatic colorectal cancer.